ERBB2 and breast carcinoma: Another clinical trial burst in 2020 was “TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases,” which provided new possibility to the treatment of refractory HER2-positive breast cancer brain metastases (17).